Biogen, Novartis, Sanofi catch a break with holdup to Celgene MS prospect
admin 28th February 2018 Uncategorised 0Companies expecting competition from Celgene multiple sclerosis candidate ozanimod just got a reprieve. The big biotech revealed late Tuesday that the FDA refused to accept its approval application because of “incomplete” pharmacology data. And that means more time for its future rivals to rack up sales unchallenged.
More: Biogen, Novartis, Sanofi catch a break with holdup to Celgene MS prospect
Source: fierce